X
Cookie Policy

CII uses cookies to improve your website & conference experiences, including enhancing website navigation, personalized features & promotions, evaluating our services, and customizing content and ads based on your preferences as you browse or engage with us. By clicking "Continue" or continuing to use our site, you are agreeing to our and our partners use of cookies. See our Privacy Policy for more information.

 
 
Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • No Cytokine Storm, ‘Bursty’ Disease Spread: Biomarkers For Elevated Risk: COVID-19 Updates

    Sep 11, 2020, 06:20 AM by Michael Croft
    Bio-IT World  | Japanese researchers argue there is no cytokine storm, computer-designed protective proteins, ELISA test for antibodies, COVID-19’s impact on Black and Hispanic communities, a “burstier” model of disease spread, and new biomarkers for elevated risk. Plus, the International Vaccine Institute preps with Gates money, 3M funds vaccine researcher, and more.
    Full story
  • SciBite launches state-of-the-art AI platform for Life Sciences organisations

    Sep 11, 2020, 06:08 AM by Michael Croft
    CAMBRIDGE, UNITED KINGDOM - Sep 11, 2020 - SciBite, the award-winning semantic technology company, today announced the launch of SciBiteAI, a state-of-the-art Artificial Intelligence software platform for leveraging machine learning models alongside semantic technologies to unlock insights into Life Sciences data
    Full story
  • Positive Technologies: Vulnerabilities in PAN-OS could threaten internal networks security

    Sep 10, 2020, 13:05 PM by Michael Croft
    FRAMINGHAM, MA, UNITED STATES - Sep 9, 2020 - Palo Alto Networks remediated vulnerabilities in PAN-OS (operating systems version 8.1 or later), which is used by Palo Alto Networks next-generation firewalls (NGFW)
    Full story
  • Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population

    Sep 10, 2020, 10:20 AM by Michael Croft
    MONTREAL, QC, CANADA - Sep 10, 2020 - Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the general population
    Full story
  • Salaso Health’s telemedicine and live exercise platform enable US healthcare teams to stay safely connected with COVID-19 patients

    Sep 10, 2020, 10:04 AM by Michael Croft
    NEW YORK, NY, UNITED STATES - Sep 10, 2020 - In the current pandemic environment, face-to-face physical therapy visits are less viable due to increasing demands on the healthcare system, as well as the enactment of stay-at-home measures and the reticence of patients particularly those from at-risk groups to visit a clinic or hospital setting
    Full story
  • Peer-reviewed Study by Optibrium Demonstrates the Value of Deep Learning for Imputation of Drug Discovery Data

    Sep 10, 2020, 06:54 AM by Michael Croft
    CAMBRIDGE, UNITED KINGDOM - Sep 9, 2020 - Optibrium™, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling [1]
    Full story
  • Dotmatics introduces eln.online to support research start-ups

    Sep 10, 2020, 06:49 AM by Michael Croft
    BISHOP'S STORTFORD, UNITED KINGDOM - Sep 9, 2020 - Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the introduction of eln
    Full story
  • Phosplatin Therapeutics Announces Two Leadership Appointments

    Sep 9, 2020, 14:39 PM by Michael Croft
    NEW YORK, NY - Sep 9, 2020 - Phosplatin Therapeutics, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the addition to its growing team of Joseph F
    Full story
  • MDI Biological Laboratory Scientists Decipher Role of a Stress Response Gene

    Sep 9, 2020, 13:27 PM by Michael Croft
    BAR HARBOR, ME, UNITED STATES - Sep 9, 2020 - Scientists have long known that chronic stress experienced early in life, or even chronic prenatal exposure to maternal stress hormones in the womb, can shorten lifespan and contribute to age-related chronic diseases like arthritis, asthma, cancer, cardiovascular disease, diabetes, heart disease and even mental illness later in life -- long after the source of stress has been removed
    Full story
  • ECCRT and IDDI establish partnership for continuous development of IDDI global team members

    Sep 9, 2020, 09:46 AM by Michael Croft
    LOUVAIN-LA-NEUVE, BELGIUM - Sep 9, 2020 - European Centre for Clinical Research Training (ECCRT)  has been selected as a premium provider for continuous online learning by IDDI, a BIOSTATISTICAL AND ECLINICAL SERVICES provider for Pharmaceutical and Biotechnology companies
    Full story
  • Beyond the Rule of 5: Vastly Expanding Targetable Drugs

    Sep 9, 2020, 07:20 AM by Michael Croft
    Bio-IT World | At the Drug Discovery Chemistry Virtual conference, researchers from industry and academia provide a glimpse into the expanse of pharmaceuticals available beyond Lipinski’s Rule of 5, an endeavor that will hopefully enable the development of much more specific agents with vastly expanded targetable options.
    Full story
  • Lifebit Appoints General Manager to Spearhead Global Expansion

    Sep 8, 2020, 15:11 PM by Michael Croft
    LONDON, UK - Sep 8, 2020 - Lifebit Biotech announced today the appointment of Frank Seo, who joins the company as General Manager
    Full story
  • Computational Tool Could Improve Clinical Success Rate Of Drugs

    Sep 8, 2020, 13:10 PM by Michael Croft
    Bio-IT World  A newly developed translatable components regression (TransComp-R) model, developed by researchers from Purdue University and the Massachusetts Institute of Technology (MIT), recently identified an overlooked biological mechanism possibly responsible for resistance to the drug infliximab commonly prescribed to patients with inflammatory bowel disease (IBD).
    Full story
  • DIASORIN AND MEMED PARTNER TO DEVELOP AND COMMERCIALIZE NOVEL HOST IMMUNE RESPONSE BASED DIAGNOSTICS SOLUTION

    Sep 8, 2020, 04:57 AM by Michael Croft
    SALUGGIA, ITALY AND HAIFA, ISRAEL - Sep 8, 2020 -   DiaSorin (FTSE MIB: DIA) and MeMed have announced today the creation of a strategic partnership to accelerate the deployment of a novel, host-protein signature-based assay
    Full story
  • First-class Chelating Agents Covering Full Range Are Available at CD Bioparticles

    Sep 7, 2020, 02:06 AM by Michael Croft
    SHIRLEY, NY, UNITED STATES - Sep 9, 2020 - Chelating agents are chemical compounds that react with metal ions to form a stable, water-soluble complex
    Full story
  • Creative Biolabs Introduces One-Stop CAR-T Preclinical In Vivo Assay Services

    Sep 6, 2020, 23:56 PM by Michael Croft
    SHIRLEY, NY, UNITED STATES - Sep 7, 2020 - Chimeric antigen receptor (CAR) T cell therapy represents the culmination of research in both immunology and oncology fields
    Full story
  • Mouse Models, Machine Learning, Triggering Proteins: COVID-19 Updates

    Sep 4, 2020, 04:25 AM by Michael Croft
    Bio-IT World   A potential new screening approach, improving immune response to vaccines, new mouse models of SARS-CoV-2, exploring ACE2 receptor activity, a protein that may trigger blood clots, the importance of placenta tissue, hopeful signs that a single vaccine can do the job, and a bioengineering technique to boost production of proteins that prompt antibody development. Plus, machine learning to help identify drug combinations that can be repurposed as potential therapies.
    Full story
  • Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion

    Sep 3, 2020, 16:15 PM by Michael Croft
    BOSTON, MA - Sep 3, 2020 - Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI
    Full story
  • Former FDA Commissioner Dr. Scott Gottlieb to address industry on sustainable innovation at CPhI Festival of Pharma

    Sep 3, 2020, 07:54 AM by Michael Croft
    AMSTERDAM, THE NETHERLANDS - Sep 3, 2020 - : CPhI Festival of Pharma (5-16 October, 2020), the world’s largest ever virtual pharma expo, unveils its ground-breaking two-week long agenda
    Full story
  • Phil Baran on the Quest to Make Chemistry Boring Again

    Sep 3, 2020, 01:10 AM by Michael Croft
    Bio-IT World | Phil Baran of Scripps Research is dedicated to simplifying chemical synthesis, not to create techniques that are “gimmicky” but will instead become the standard processes of the future. Maybe, “fifty years from now,” he predicts, “we’ll look back in curiosity at chemists of our age who had stages in their syntheses instead of making everything in 1-3 steps.”
    Full story
  • «
  • 191
  • 192 (current)
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy